miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1

Wang,Yan; Sun,Hai‑Hong; Sui,Ming‑Hua; Ma,Jun‑Jie

doi:10.3892/ol.2017.7220

miR‑218 inhibits acute promyelocytic leukemia cell growth by targeting BMI‑1

Authors:
- Yan Wang
- Hai‑Hong Sun
- Ming‑Hua Sui
- Jun‑Jie Ma
View Affiliations

Affiliations: Department of Hematology, Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Department of Emergency Intensive Care Unit, Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Department of Medical Oncology, Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China
Published online on: October 19, 2017 https://doi.org/10.3892/ol.2017.7220
Pages: 8078-8083

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myelocytic leukemia. Previous studies have reported a number of functions and therapeutic roles of microRNAs (miRs) in APL, and have suggested that miR‑218 acts as a tumor suppressor in a number of types of human cancer; however, its role in APL remains unclear. In the present study, the expression of miR‑218 and its effects on the viability and proliferation of HL‑60 cells was investigated. Reverse transcription‑quantitative polymerase chain reaction analysis demonstrated that miR‑218 was frequently downregulated in APL marrow tissues compared with normal marrow tissues. Overexpression of miR‑218 significantly inhibited cell proliferation, arrested the cell cycle in the G0/G1 phase and induced apoptosis. In addition, B‑cell‑specific Moloney murine leukemia virus integration site 1 (BMI‑1) mRNA expression was negatively associated with miR‑218 expression; BMI‑1 mRNA and protein expression were downregulated following transfection with miR‑218 mimic. These results indicate that miR‑218 functions as tumor suppressor in APL, and the miR‑218/BMI‑1 signaling axis may be a potential novel diagnostic marker and therapeutic target for the treatment of APL.

View Figures

View References

1	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
2	Imani-Saber Z and Ghafouri-Fard S: Promyelocytic leukemia gene functions and roles in tumorigenesis. Asian Pac J Cancer Prev. 15:8021–8028. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ganzel C and Douer D: Extramedullary disease in APL: A real phenomenon to contend with or not? Best Pract Res Clin Haematol. 27:63–68. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sandhu S and Mulligan SP: Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica. 100:411–414. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chen SJ: A potential target of Tanshinone IIA for acute promyelocytic leukemia revealed by inverse docking and drug repurposing. Asian Pac J Cancer Prev. 15:4301–4305. 2014. View Article : Google Scholar : PubMed/NCBI
6	Liang H, Li X, Wang L, Yu S, Xu Z, Gu Y, Pan Z, Li T, Hu M, Cui H, et al: MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells. Cell Physiol Biochem. 32:1818–1829. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sharifi M, Salehi R, Gheisari Y and Kazemi M: Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. Mol Biol Rep. 41:2799–2808. 2014. View Article : Google Scholar : PubMed/NCBI
8	Tu K, Li C, Zheng X, Yang W, Yao Y and Liu Q: Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth. Oncol Rep. 32:1571–1577. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wang F, Ren X and Zhang X: Role of microRNA-150 in solid tumors. Oncol Lett. 10:11–16. 2015.PubMed/NCBI
10	Zhao J, Lu Q, Zhu J, Fu J and Chen YX: Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 9:762014. View Article : Google Scholar : PubMed/NCBI
11	Zhang H, Luo XQ, Feng DD, Zhang XJ, Wu J, Zheng YS, Chen X, Xu L and Chen YQ: Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 10:1082011. View Article : Google Scholar : PubMed/NCBI
12	Dong Y, Zou J, Su S, Huang H, Deng Y, Wang B and Li W: MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma. Mol Med Rep. 12:1016–1022. 2015. View Article : Google Scholar : PubMed/NCBI
13	Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 62:229–235. 2012. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Miftakhova R, Sandberg T, Hedblom A, Nevzorova T, Persson JL and Bredberg A: DNA methylation in ATRA-treated leukemia cell lines lacking a PML-RAR chromosome translocation. Anticancer Res. 32:4715–4722. 2012.PubMed/NCBI
16	Liu WJ, Jiang NJ, Guo QL and Xu Q: ATRA and As₂O₃ regulate differentiation of human hematopoietic stem cells into granulocyte progenitor via alteration of HoxB8 expression. Eur Rev Med Pharmacol Sci. 19:1055–1062. 2015.PubMed/NCBI
17	Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M and Enokida H: Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sharifi M, Salehi R, Gheisari Y and Kazemi M: Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. Mol Biol Rep. 41:2799–2808. 2014. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Zhu X, Gu J, Hu H, Dong D, Yao J, Lin C and Fei J: Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology. 15:215–221. 2010. View Article : Google Scholar : PubMed/NCBI
20	Cheng MW, Wang LL and Hu GY: Expression of microRNA-218 and its clinicopathological and prognostic significance in human glioma cases. Asian Pac J Cancer Prev. 16:1839–1843. 2015. View Article : Google Scholar : PubMed/NCBI
21	Jin J, Cai L, Liu ZM and Zhou XS: miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhang X, Tian T, Sun W, Liu C and Fang X: Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. Medicine (Baltimore). 96:e73462017. View Article : Google Scholar : PubMed/NCBI
23	Lin X, Ojo D, Wei F, Wong N, Gu Y and Tang D: A novel aspect of tumorigenesis-BMI1 functions in regulating DNA damage response. Biomolecules. 5:3396–3415. 2015. View Article : Google Scholar : PubMed/NCBI
24	Meng S, Luo M, Sun H, Yu X, Shen M, Zhang Q, Zhou R, Ju X, Tao W, Liu D, et al: Identification and characterization of Bmi-1-responding element within the human p16 promoter. J Biol Chem. 285:33219–33229. 2010. View Article : Google Scholar : PubMed/NCBI